National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 53 of 2009)

Overview

The National Health Act 1953, as amended by the legislative instrument F2009L02293, aims to regulate the Pharmaceutical Benefits Scheme (PBS) and ensure affordable access to medicines for Australians. Enacted by the Australian Parliament, the Act facilitates the Commonwealth's provision of reliable and timely pharmaceutical benefits through Part VII. The 2009 amendment determination, effective from 1 July 2009, updates the conditions under which payments for pharmaceutical benefits are made by approved pharmacists and approved medical practitioners. This amendment follows consultations with the Pharmaceutical Benefits Advisory Committee (PBAC), which includes representatives from various healthcare interests and professions, to recommend changes to the Minister for consideration. The amendments include the addition of certain listed drugs to the PBS and the removal of specific forms of oestradiol and oestradiol with norethisterone from the list of covered pharmaceutical items.

Scope and Application

The National Health Act 1953 Amendment Determination under paragraph 98C(1)(b) governs the conditions under which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This instrument, which commenced on 1 July 2009, amends the previous determination made by legislative instrument number PB 119 of 2008. The amendments, outlined in Schedule 1, include the addition of Metformin and Mupirocin to the list of drugs eligible for benefits, as well as the deletion of certain forms of Oestradiol and Oestradiol with Norethisterone from the list of eligible drugs. The Act applies to the Pharmaceutical Benefits Scheme (PBS), which is designed to provide reliable, timely, and affordable access to a wide range of medicines for all Australians. The instrument extends to the entire Commonwealth of Australia, ensuring uniform application of the provisions across the nation. The changes are made following consultations with the Pharmaceutical Benefits Advisory Committee, which includes representatives from various health-related fields, and take into account submissions from interested pharmaceutical companies.

Key Provisions

The main operative sections of this legislation are primarily found in the Schedule, which amends the previous determination under section 98C(1)(b) of the National Health Act 1953. This amendment, effective from 1 July 2009, includes both additions and deletions of listed drugs, specifically Metformin and Mupirocin as additions, and certain forms of Oestradiol and Oestradiol with Norethisterone as deletions. These changes are pivotal as they dictate which pharmaceutical benefits will be provided under the Pharmaceutical Benefits Scheme (PBS), ensuring that Australians have access to essential medicines. The Minister's role in determining these drugs and their forms, as outlined in sections 85(2) to 85(6), is crucial in shaping the healthcare landscape by specifying which medicines will be subsidized and how they will be administered. The obligations imposed by this Act on the parties involved are significant and multifaceted. The Minister is tasked with declaring drugs and medicinal preparations to be listed drugs under subsection 85(2), ensuring they meet the criteria for inclusion in the PBS. Additionally, the Minister must determine the form and administration of these listed drugs, which includes specifying the brand of the pharmaceutical item (subsection 84(1)). Furthermore, the Act requires that the Minister establish conditions under which payments will be made for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners, as stipulated in section 98C(1)(b). These obligations ensure a structured and regulated approach to the provision of pharmaceutical benefits, maintaining the integrity and accessibility of the PBS. The legislation outlines various consequences for breaches and non-compliance with its provisions. While the Act does not explicitly detail criminal penalties, breaches of its conditions could potentially lead to civil penalties or administrative actions. For instance, failure to comply with the declared forms and brands of listed drugs, or the specified conditions for payments, could result in fines or other corrective measures. Additionally, any entity or individual found to be in breach of the Act’s requirements could face legal action, impacting their ability to operate within the PBS framework. The exact penalties are not detailed in the Act but are subject to interpretation and enforcement by relevant authorities.